Trending

biotechnology

Moderna’s $37B market cap is too high, despite COVID-19 vaccine; analyst

Moderna’s $37B market cap is too high, despite COVID-19 vaccine; analyst

JP Morgan has downgraded its valuation of Moderna, saying its $37 billion market cap is way too high

X

Moderna’s $37B market cap is too high, despite COVID-19 vaccine; analyst

https://pharmaphorum.com/news/modernas-37b-market-cap-is-too-high-despite-covid-19-vaccine-analyst/

Talks from the MHRA, Innovate UK, Plasticell and more

Talks from the MHRA, Innovate UK, Plasticell and more

Cell and Gene Therapy

X

Talks from the MHRA, Innovate UK, Plasticell and more

https://pharmaphorum.com/partner-content/talks-from-the-mhra-innovate-uk-plasticell-and-more/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com